Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29169174 | 0.88 | KDM4E (0.44) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL25075368 | 0.88 | KDM4E (0.44) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL29168963 | 0.80 | KDM4E (0.41) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL29168967 | 0.80 | KDM4E (0.41) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL12180387 | 0.79 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL29343021 | 0.78 | KDM4E (0.69) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL15971349 | 0.78 | KDM4E (0.55) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL31046584 | 0.78 | KMT2A (0.40) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL23535252 | 0.78 | NOTUM (0.42) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL13522484 | 0.78 | KDM5A (0.48) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2003132-B1 | Oxadiazole derivatives as S1P1 agonists | ASTELLAS PHARMA INC (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-2003132-A1 | HETERO COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039889-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | ALDH1A1 427/4885KDM4E 4128/4885HPGD 274/4885 |
| US-20100168159-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | ALDH1A1 3640/4885KDM4E 4796/4885HPGD 4279/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | ALDH1A1 3640/4885KDM4E 4796/4885HPGD 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.